Pulmonary arterial hypertension (PAH) is defined as an intractable disease characterized by a progressive elevation of pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP), leading to right heart failure and premature death. The five-year survival rate after diagnosis is approximately 57%.
Introduction
Pulmonary arterial hypertension (PAH) is caused by functional and structural changes in the pulmonary vasculature that can lead to increased pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP). The elevated PAP induces extensive changes in heart structure followed by right heart failure, and evenEnhanced CaSR function in PAH -9 -tually death. PAH is clinically defined by PAP chronically increasing due to various causes and resting mean PAP being ≥25 mmHg. The total number of PAH patients is estimated to by approximately 100,000 globally.
The five-year survival rate of this condition after diagnosis is ~57%. The mean duration between symptom onset and diagnostic catheterization is 2.8 years. In the United States, the mean age of PAH patients was 36.4 years in the 1980s, but it was 53.0 years in 2007 due to improved diagnosis, treatment, and management (1, 2) .
Clinical classification of pulmonary hypertension
Pulmonary hypertension falls into five diagnostic classifications in terms of its pathogenesis (3, 4) ( Table   1 ). Group 1 is PAH that may occur in different clinical conditions depending on the associated disease. This Table 1 . Clinical classification of pulmonary hypertension (Dana Point, 2008) subgroup includes patients with idiopathic PAH (IPAH) corresponding to sporadic disease in which there is neither family history of PAH nor an identified risk factor, as well as patients with heritable PAH (HPAH) with germline mutations in the bone morphogenetic protein receptor type 2 (BMPR2), activin receptor-like kinase type 1 (ALK1), and endoglin genes. PAH can also be induced by some drugs and chemicals. In addition, PAH associated with connective tissue disease (CTD), human immunodeficiency virus (HIV) infection, portal hypertension, and congenital heart disease (CHD) represents an important clinical subgroup. Group 2 is pulmonary hypertension with left heart disease including left-sided ventricular or valvular disease that may produce an increase in left arterial pressure, with passive backward transmission of the pressure leading to increased PAP. Group 3 is pulmonary hypertension due to lung diseases and/or hypoxia. The predominant cause in this group is alveolar hypoxia as a result of lung disease, impaired control of breathing, or chronic exposure to high altitude. Group 4 is chronic thromboembolic pulmonary hypertension (CTEPH). The incidence of CTEPH is unclear, but it occurs in ~4% of patients after an acute pulmonary embolism. Group 5 consists of several forms of pulmonary hypertension for which the etiology is unclear and/or multifactorial.
Drug therapy for PAH
On the basis of our understanding of the pathological mechanisms of PAH, drug therapy for PAH has progressed in recent years via the development of several specific drugs that offer an effective alternative to voltage-dependent Ca 2+ channel blockers such as nifedipine and diltiazem (4) (Fig. 1A) . Epoprostenol (prostacyclin, also known as prostaglandin I 2 , PGI 2 ; Fig. 1B ), a potent vasodilator produced by vascular endothelium, was the first drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of PAH. Epoprostenol improves exercise capacity, hemodynamics, and quality of life (QOL), as well as improving survival in PAH patients. Two prostacyclin analogues, treprostinil and iloprost, are also available for PAH treatment.
In the pathophysiology of PAH, endothelin plays a key role for exerting vasoconstrictor and mitogenic effects by binding to endothelin receptors in pulmonary arterial smooth muscles. Bosentan (Fig. 1C) , an endothelin receptor antagonist, improves exercise capacity, hemodynamics, and clinical deterioration. There is also ambrisentan, a selective endothelin receptor (ET A ) antagonist for the treatment of PAH. In addition, two phosphodiesterase type 5 (PDE5) inhibitors, sildenafil and tadalafil (Fig. 1D ), which increase cGMP and have been used to treat erectile dysfunction (ED), are also approved for PAH treatment. Specific pulmonary vasodilators have now been approved for treatment of PAH; moreover, numerous potential candidates either have been submitted for approval or are in development. Despite recent major therapeutic advances, no current treatments of PAH can cure this life-threatening disease.
Enhanced Ca 2+ signaling in pulmonary myocytes from IPAH patients
The pathogenic mechanisms involved in the pulmonary vascular abnormalities including sustained pulmonary vasoconstriction and vascular remodeling in IPAH patients remain unclear. Sustained vasoconstriction and vascular remodeling owing to proliferation of pulmonary arterial smooth muscle cells (PASMCs) are major pathogenic events that lead to early morbidity and mortality. Excessive PASMC proliferation is predominantly caused by increased production of vasoconstrictive and mitogenic agonists, and increased proliferation ] cyt rise in IPAH-PASMCs. The protein expression level of CaSR in PASMCs and lung tissues from IPAH patients was greater than that from normal subjects (Fig. 2B) . Down- 
Structure of CaSR
CaSR was originally cloned from bovine parathyroid glands, which secrete parathyroid hormone (PTH), an extracellular Ca 2+ -elevating hormone (13) . CaSR (also known as GPRC2A) belongs to family C of the G protein-coupled receptor (GPCR) superfamily, which includes the metabotropic glutamate receptors (mGluRs), GABA B receptors, and taste receptors as well as orphan receptors (14, 15) (Fig. 3) . Human CaSR consists of 
Modulators of CaSR
CaSR can be activated by several endo/exogenous ligands including polyvalent cations (Ca treatment for osteoporosis or hypocalcemia due to the increased sensitivity of CaSR to extracellular Ca 2+ (14, 15) . ] cyt were observed in PASMCs isolated from two different animal models of pulmonary hypertension: monocrotaline (MCT)-induced pulmonary hypertension in rats and hypoxia-induced pulmonary hypertension (HPH) in mice (12, 19, 20) . Finally, intraperitoneal injection of the calcilytic NPS2143 prevented the development of pulmonary hypertension and right ventricular hypertrophy in experimental animal models of pulmonary hypertension. Pulmonary hypertension characterized by increased right ventricular systolic pressure (RVSP; Fig. 5A ) and vascular remodeling (Fig. 5B ) in animal models, was improved by NPS2143. Pharmacological blockade of the upregulated CaSR with calcilytics may be a novel therapeutic approach for PAH patients who do not respond to the conventional drug therapy.
Calcilytics block development of pulmonary hypertension

Conclusion
We recently found that CaSR is upregulated in PASMCs isolated from patients with IPAH and animals with experimental pulmonary hypertension (12, 19, 20) . The upregulated CaSR is necessary for the enhanced 
